Impact of TREM1 Variants on the Risk and Prognosis of Glioma in the Chinese Han Population

Figures & data

Table 1 Demographic and Clinical Information About Participants

Variants	Overall Survival				Progression-Free Survival
	Total	Event	χ^2	Log-Rank p-value	Total	Event	χ^2	Log-Rank p-value
Gender
Male	307	273	1.014	0.314	305	271	1.541	0.214
Female	251	226			248	224
Age
<40 years old	248	214	3.559	0.059	244	211	2.714	0.100
≥40 years old	310	285			309	284
WHO grade
I–II	352	310	1.201	0.273	350	308	1.214	0.271
III–IV	206	189			203	187
Operation
NTR/STR	175	173	28.734	p < 0.001	172	170	36.086	p < 0.001
GTR	383	326			381	325
Radiotherapy
No	57	46	2.121	0.346	54	43	5.588	0.061
Conformal radiotherapy	145	119			144	118
Gamma knife	356	334			355	334
Chemotherapy
No	331	309	17.541	p < 0.001	330	308	3.699	0.054
Yes	227	190			223	187
Progress
No	31	0	104.726	p < 0.001	31	0	104.503	p < 0.001
Yes	522	495			522	495

Notes: Log-rank p-values were calculated by Chi-Square test. Bold type indicated statistical significance (p < 0.05).

Abbreviations: WHO, World Health Organization; NTR, Near-total resection; STR, Sub-total resection; GTR, Gross-total resection.

Table 2 The Basic Information About Selected SNPs

SNP-ID	Chr	Gene	Position	Alleles	MAF		p-value HWE	OR (95% CI)	p-value
					Case	Control
rs9369269	6	TREM1	41236513	A/C	0.530	0.491	0.475	1.17(0.99–1.39)	0.070
rs4714447	6	TREM1	41239822	C/T	0.339	0.355	0.696	0.93(0.78–1.12)	0.442
rs2170887	6	TREM1	41241292	C/A	0.504	0.487	0.476	1.07(0.90–1.27)	0.447
rs2234242	6	TREM1	41244020	C/G/T	0.259	0.268	0.649	0.95(0.78–1.16)	0.623
rs1351835	6	TREM1	41244499	T/A	0.250	0.265	0.488	0.92(0.76–1.12)	0.414
rs2234237	6	TREM1	41250466	T/A	0.311	0.311	0.602	1.00(0.83–1.20)	0.984

Notes: p-value was calculated by Pearson’s chi-square test. Bold type indicates statistical significance (p < 0.05).

Abbreviations: SNP, Single nucleotide polymorphism; Chr, Chromosome; MAF, Minor allele frequency; HWE, Hardy-Weinberg equilibrium.

Table 3 The Overall Association Analysis of TREM1 Variants with Glioma Susceptibility in Genetic Models

SNP-ID	Model	Genotype	Frequency		With Adjustment
			Case	Control	OR (95% CI)	p-value
rs9369269	Codominant	A/A	113	134	1
		A/C	298	242	1.46(1.08–1.97)	0.014
		C/C	147	125	1.40(0.99–1.97)	0.058
	Dominant	A/A	113	134	1
		C/C-A/C	445	367	1.44(1.08–1.91)	0.013
	Recessive	A/A-A/C	411	376	1
		C/C	147	125	1.08(0.82–1.42)	0.590
	Log-additive	–	–	–	1.18(0.99–1.40)	0.065
rs4714447	Codominant	C/C	240	210	1
		C/T	254	224	0.82(0.55–1.20)	0.944
		T/T	61	65	0.99(0.77–1.28)	0.331
	Dominant	C/C	240	210	1
		T/T-C/T	315	289	0.95(0.75–1.22)	0.699
	Recessive	C/T-C/C	494	434	1
		T/T	61	65	0.83(0.57–1.20)	0.314
	Log-additive	–	–	–	0.93(0.78–1.12)	0.441
rs2170887	Codominant	C/C	131	136	1
		C/A	292	243	1.14(0.81–1.61)	0.142
		A/A	135	123	1.25(0.93–1.67)	0.450
	Dominant	C/C	131	136	1
		A/A-C/A	427	366	1.21(0.92–1.60)	0.176
	Recessive	C/A-C/C	423	379	1
		A/A	135	123	0.99(0.74–1.31)	0.919
	Log-additive	–	–	–	1.07(0.90–1.27)	0.439
rs2234242	Codominant	G/G	307	270	1
		G/A	209	192	0.90(0.56–1.45)	0.748
		A/A	39	38	0.96(0.74–1.24)	0.671
	Dominant	G/G	307	270	1
		A/A-G/A	248	230	0.95(0.74–1.21)	0.676
	Recessive	A/A-G/G	516	462	1
		A/A	39	38	0.92(0.58–1.46)	0.716
	Log-additive	–	–	–	0.95(0.79–1.16)	0.630
rs1351835	Codominant	T/T	308	270	1
		T/A	208	186	0.76(0.46–1.25)	0.856
		A/A	33	38	0.98(0.75–1.26)	0.283
	Dominant	T/T	308	270	1
		A/A-T/A	241	224	0.94(0.74–1.20)	0.621
	Recessive	T/A-T/T	516	456	1
		A/A	33	38	0.77(0.47–1.25)	0.289
	Log-additive	–	–	–	0.92(0.76–1.12)	0.409
rs2234237	Codominant	T/T	272	240	1
		T/A	224	209	1.05(0.70–1.59)	0.665
		A/A	61	51	0.94(0.73–1.22)	0.803
	Dominant	T/T	272	240	1
		A/A-T/A	285	260	0.97(0.76–1.23)	0.780
	Recessive	T/A-T/T	496	449	1
		A/A	61	51	1.08(0.73–1.60)	0.697
	Log-additive	–	–	–	1.00(0.83–1.20)	0.977

Notes: p-value was calculated by logistic regression analysis adjusted for gender and age. Bold type indicate statistical significance (p < 0.05).

Abbreviations: SNP, Single nucleotide polymorphism; OR, odds ratio; 95% CI, 95% confidence interval.

Figure 1 Overall analyses for the association between TREM1 variants and glioma susceptibility.

Abbreviations: CI, Confidence interval; OR, Odds ratio.

Table 4 The Association Between rs9369269 and rs4714447 and Glioma Susceptibility After Age- and Gender-Stratified Analyses

SNP	Model	Genotype	≥40		≤40		Male		Female
			OR (95% CI)	p-value	OR (95% CI)	p-value	OR(95% CI)	p-value	OR(95% CI)	p-value
rs9369269	Codominant	A/A	1		1		1		1
		A/C	1.41(0.92–2.15)	0.113	1.31(0.86–2.01)	0.213	1.28(0.87–1.89)	0.203	1.50(0.96–2.37)	0.077
		C/C	1.59(0.98–2.57)	0.060	0.74(0.44–1.24)	0.254	0.89(0.56–1.4)	0.605	1.94(1.13–3.35)	0.017
	Dominant	A/A	1		1		1		1
		C/C-A/C	1.47(0.99–2.18)	0.058	1.11(0.74–1.66)	0.611	1.14(0.79–1.63)	0.485	1.62(1.05–2.50)	0.029
	Recessive	A/A-A/C	1		1		1		1
		C/C	1.27(0.86–1.88)	0.236	0.62(0.40–0.95)	0.028	0.76(0.52–1.11)	0.158	1.46(0.94–2.27)	0.093
	Log-additive	–	1.26(0.99–1.60)	0.061	0.88(0.68–1.13)	0.316	0.96(0.76–1.20)	0.692	1.40(1.06–1.83)	0.016
rs4714447	Codominant	C/C	1		1		1		1
		T/C	1.02(0.70–1.47)	0.932	0.98(0.68–1.43)	0.926	0.99(0.70–1.41)	0.965	0.99(0.68–1.45)	0.955
		T/T	0.60(0.34–1.03)	0.064	1.07(0.59–1.94)	0.827	0.79(0.48–1.31)	0.359	0.87(0.46–1.66)	0.673
	Dominant	C/C	1		1		1		1
		T/T-C/T	0.90(0.64–1.27)	0.551	1.00(0.70–1.42)	0.992	0.94(0.68–1.31)	0.712	0.97(0.67–1.39)	0.860
	Recessive	C/T-C/C	1		1		1		1
		T/T	0.59(0.35–0.99)	0.046	1.08(0.61–1.90)	0.792	0.79(0.49–1.27)	0.335	0.88(0.48–1.61)	0.671
	Log-additive	–	0.83(0.65–1.07)	0.158	1.15(0.88–1.50)	0.906	0.91(0.72–1.16)	0.457	0.95(0.72–1.26)	0.741

Notes: p-value was calculated by logistic regression analysis adjusted for gender and age. Bold type indicated statistical significance (p < 0.05).

Abbreviations: SNP, Single nucleotide polymorphism; OR, odds ratio; 95% CI, 0.95% confidence interval.

Figure 2 Multifactor dimensionality reduction (MDR) was completed to assess the interaction among SNPs in TREM1 to predict glioma risk.